Comparison of Two Different Regional Analgesia Techniques for Patients Undergoing Total Knee Arthroplasty (PIPACK)

February 8, 2024 updated by: Eric Albrecht, Centre Hospitalier Universitaire Vaudois

Analgesic Efficacy of IPACK Versus Selective Tibial Nerve Block in Patients Undergoing Total Knee Arthroplasty Under Spinal Anesthesia With an Adductor Canal Block: a Randomized Controlled Double-blinded Trial

The objective of this clinical trial is to compare two regional analgesia techniques in patients undergoing total knee arthroplasty: IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) vs selective tibial nerve block. The main question is whether one of these peripheral blocks is more effective in reducing postoperative pain than the other. All patients will have a spinal block with an adductor canal block. One group will receive an IPACK block and the other group, a selective tibial nerve block. Postoperative pain scores and morphine consumption, among others, will be compared between groups.

Study Overview

Detailed Description

The aim of this randomized controlled double blinded trail is to compare an analgesic effect of an IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) block vs selective tibial nerve block in patients scheduled for total knee arthroplasty under spinal anesthesia with an adductor canal block.

The investigators presume that association of a selective tibial nerve block with an adductor canal block provides better postoperative analgesia than a combination of an IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) block with an adductor canal block. The research team plan on including 100 patients and randomly assign them to two groups of 50 patients each. After written informed consent, patients will be allocated to one of the groups, following a computer-generated list of randomization. All patients will receive central spinal anesthesia with 12.5 mg of hyperbaric bupivacaine with 100 mcg of morphine and an adductor canal block with 150 mg of ropivacaine. IPACK block group will then receive an IPACK block with 38 mg of ropivacaine and a tibial nerve group will receive a selective tibial nerve block with 37.5 mg of ropivacaine.

During the surgery, iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg. will be administered to all patients.

After surgery, all patients will be prescribed an iv patient-controlled analgesia (PCA) of morphine (boluses of 2 mg available every 10 min, maximum of 40 mg every 4 hours) along with oral acetaminophen (1000 mg every 6 h) and oral ibuprofen (400 mg every 8 hours). Oral ondansetron 4 mg every 8 hours will be available on request in case of nausea or vomiting.

The primary outcome will be the cumulative iv morphine consumption at 24 h postoperatively. Secondary outcomes will include pain- and functional-related outcomes. Pain related outcomes are cumulative morphine consumption in the recovery room, at day 1, day 2 and day 3 postoperatively, rest and dynamic pain scores, duration of peripheral nerve block defined as the time between the execution of the block and the first dose of iv morphine, incidence of postoperative nausea and vomiting and pruritus during 3 days following surgical intervention, incidence of peroneal nerve block and complications of peripheral nerve blocks.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Vaud
      • Lausanne, Vaud, Switzerland, 1011
        • Recruiting
        • University Hospital of Lausanne
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • American Society of Anesthesiologists classification I-III
  • 18 yo or older
  • patients scheduled for total knee arthroplasty under central spinal anesthesia
  • informed consent signed

Exclusion Criteria:

  • Refusal or inability for informed consent
  • Known allergies to ropivacaine, acetaminophen, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone
  • Secondary surgical revision
  • Opioid treatment such as morphine, hydrocodone, hydromorphone, tramadol, methadone, fentanyl, buprenorphine or codeine
  • Bleeding diathesis
  • Neurological deficit
  • Known renal insufficiency (eGFR <45 ml/min)
  • Known hepatic insufficiency (Child score B or C)
  • Alcohol abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: IPACK group
IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) block
The IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where nineteen mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anesthetics will be observed above the posterior capsule.
Experimental: Tibial nerve group
selective tibial nerve block
The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anesthetics around the nerve.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total iv morphine consumption
Time Frame: 24 hours postoperatively
consumption in mg
24 hours postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morphine consumption in the recovery room
Time Frame: From admission till discharge from the recovery room, up to 2 hours
consumption in mg
From admission till discharge from the recovery room, up to 2 hours
PCA administered morphine consumption
Time Frame: at day 1, day 2 and day 3 postoperatively
consumption in mg administered by PCA
at day 1, day 2 and day 3 postoperatively
rest and dynamic pain scores
Time Frame: at day 1, day 2 and day 3 postoperatively
Visual Analogue scale(VAS), 0-10 where 0 is no pain and 10 is the worst pain imaginable
at day 1, day 2 and day 3 postoperatively
Duration of peripheral nerve block
Time Frame: From execution of a peripheral nerve block till administration of a first dose of iv morphine, up to 48 hours
Time between execution of a peripheral nerve block and the first dose of iv morphine
From execution of a peripheral nerve block till administration of a first dose of iv morphine, up to 48 hours
Incidence of postoperative nausea and vomiting
Time Frame: at day 1, day 2 and day 3 postoperatively
Presence of nausea and vomiting in the postoperative period
at day 1, day 2 and day 3 postoperatively
Incidence of pruritus
Time Frame: at day 1, day 2 and day 3 postoperatively
Presence of pruritus
at day 1, day 2 and day 3 postoperatively
peroneal nerve block
Time Frame: at day 1, day 2 and day 3 postoperatively
presence of peroneal nerve block
at day 1, day 2 and day 3 postoperatively
complications of peripheral nerve blocks
Time Frame: at the moment of execution of the block (day 0) and at day 3 postoperatively
iv injection, hematoma, infection
at the moment of execution of the block (day 0) and at day 3 postoperatively
passive and active motion range
Time Frame: at day 3 postoperatively
joint motion in degrees
at day 3 postoperatively
quadriceps strength
Time Frame: at day 3 postoperatively
Percentage of strength as compared with the opposite leg
at day 3 postoperatively
walking distance
Time Frame: at 72h postoperatively
walking distance without pain
at 72h postoperatively
hospital stay
Time Frame: from admission to the hospital till discharge, up to 3 days
length of hospital stay in days
from admission to the hospital till discharge, up to 3 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2024

Primary Completion (Estimated)

July 12, 2025

Study Completion (Estimated)

July 18, 2025

Study Registration Dates

First Submitted

November 30, 2023

First Submitted That Met QC Criteria

December 11, 2023

First Posted (Actual)

December 22, 2023

Study Record Updates

Last Update Posted (Actual)

February 9, 2024

Last Update Submitted That Met QC Criteria

February 8, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Pain

Clinical Trials on IPACK block

Subscribe